Rexahn receives patent for new cancer compounds

The patent covers Rexahn’s anticancer candidate, RX-0183 and related compounds, and are targeted, small molecule quinazoline analogues that inhibit key molecules such as c-Fos and Akt proteins. Akt and c-Fos proteins are cancer cell signaling targets involved in transduction, growth and proliferation.

Preclinical studies showed that RX-0183 inhibited in vitro proliferation of cancer cells derived from many human solid tumors. It also inhibited tumor growth in xenograft human tumor models. Based on the preclinical data, RX-0183 demonstrates potent anticancer activity for treating multiple cancers.

Chang Ahn, chairman and CEO of Rexahn, said: “Obtaining patent coverage for these anticancer compounds marks another important milestone, as we continue to broaden our product pipeline to include new, innovative therapies for various types of cancer.”